助手标题  
全文文献 工具书 数字 学术定义 翻译助手 学术趋势 更多
查询帮助
意见反馈
   膀胱癌复发 的翻译结果: 查询用时:0.033秒
图标索引 在分类学科中查询
所有学科
肿瘤学
泌尿科学
更多类别查询

图标索引 历史查询
 

膀胱癌复发
相关语句
  bladder cancer recurrence
     Intravesical instillation of IL-2 together with pirarubicin in the prevention of bladder cancer recurrence
     IL-2联合吡柔比星膀胱灌注预防膀胱癌复发
短句来源
     Conclusion Seguential and alternate intravesical instilation of MMC BCG and THP is an effective means of preventing bladder cancer recurrence.
     结论 MMC、BCG和THP多药序联交替膀胱灌注治疗和预防膀胱癌复发副作用轻 ,效果良好
短句来源
     Prevention of Bladder Cancer Recurrence by Submucous Injection and Infusion of THP plus IL-2 into the Bladder in Combination with Chinese Traditional Medicine
     吡柔比星联合IL-2膀胱黏膜下注射和灌注结合中药预防膀胱癌复发
短句来源
     Whole bladder wall laser irradiation to prevent bladder cancer recurrence with intravesical HpD and ascorbic acid
     膀胱内灌注血卟啉衍生物加抗坏血酸全膀胱激光照射预防膀胱癌复发
短句来源
     Clinical study on the effect of intravesical instillation of antifibrinolytic agents with bacillus Calmette-Guerin in preventing bladder cancer recurrence
     膀胱内灌注纤维蛋白溶解抑制药物对卡介苗抗膀胱癌复发作用影响的临床研究
短句来源
更多       
  recurrence of bladder cancer
     The future recurrence of bladder cancer in the former was 5 cases (45.5%),but 0(0/25) in the latter, and the two percentages were significantly different.
     经随诊前者膀胱癌复发 5例 (45 .5 % ) ,后者为 0 (0 2 5 ) ,两者复发百分比有显著性差异 ,相对危险性 (RR)为 12 5 0。
短句来源
     The recurrence rate of the cases treated with HCPT was 25.5%(14/55), and 7.6% in the cases treaded with HCPT and IL-2. There was much difference between the two rates,χ 2=4.06, P<0.05. So,it is much better to use HCPT and IL-2 than to use HCPT alone to prevent the recurrence of bladder cancer.
     HCPT +IL 2组复发率为 7.6% ( 5 /66) ,两者差异有统计学意义 ,χ2 =4 0 6,P <0 0 5。 初步研究结果提示 ,HCPT +IL 2较单独HCPT膀胱灌注预防膀胱癌复发效果更好
短句来源
     ConclusionThe effect of intravesical instillation of Brucea Javanica oil emulsion to prevent the recurrence of bladder cancer after TUR-Bt operation is favorable.
     结论TUR-Bt术后灌注鸦胆子油乳预防膀胱癌复发有良好效果。
短句来源
     Intravesical instillation of cytotoxic T-lymphocytes induced by soluble tumor antigen in the prophylaxis of recurrence of bladder cancer
     肿瘤抗原诱导的T淋巴细胞膀胱灌注预防膀胱癌复发
短句来源
     Conclusions:This technique have good effect on preventing of the postoperative recurrence of bladder cancer.
     结论 :髂内动脉置化疗泵行膀胱区域化疗 ,预防膀胱癌复发效果良好 ,适用于有复发倾向的膀胱癌患者。
短句来源
  bladder tumor recurrence
     Prevention of bladder tumor recurrence by injecting IL-2 into the bladder incision edges and instilling IL-2 and BCG intravesically
     膀胱切缘注射白细胞介素2及术后灌注白细胞介素2加卡介苗预防膀胱癌复发(附33例报告)
短句来源
     2. Find out the relation between complement regulator factor H and related protein and bladder tumor recurrence.
     2.探讨H因子及其相关蛋白在膀胱癌细胞上表达情况与膀胱癌复发间的关系;
短句来源
  “膀胱癌复发”译为未确定词的双语例句
     Grade regression after recurrence in primary T_1G_3 bladder cancer
     原发性T_1G_3膀胱癌复发后病理分级减低现象的临床意义
短句来源
     Relationshiop among the expression and interaction of p53,p21~(WAF1/CIP1) and CyclinE genes and human bladder carcinoma recurrence
     膀胱癌复发与p53、p21~(WAF1/CIP1)和细胞周期素E基因表达的相关性研究
短句来源
     Result:There were 2 cases recurranted in bladder in 5 year fellow-up, the 1 , 2, 5 yeas survival rate were 100% (9/9), 88.8% (8/9) and 66.7% (6/9), respectively.
     结果 :9例输尿管癌包括T3 4例和T2 4例中 ,各有 1例膀胱癌复发 ,其余无尿路上皮肿瘤复发 ,其生存率 1年为 10 0 % ,2年为 88.8% ,5年为 6 6 .7%。
短句来源
     Preventing the recurrence of bladder carcinoma by submucous injecting 5-Fu
     粘膜下注射5-Fu预防膀胱癌复发
短句来源
     The survivin expression positive rate in recurrent cases was 62.5%( 15/24) and in non-recurrent cases being 36.4%(16/44).
     膀胱癌复发者24例,其中15例Survivin表达阳性,阳性率62.5%(15/24); 无复发者44例,其中16例Survivin表达阳性,阳性率36.4%(16/44)。
短句来源
更多       
查询“膀胱癌复发”译词为用户自定义的双语例句

    我想查看译文中含有:的双语例句
例句
为了更好的帮助您理解掌握查询词或其译词在地道英语中的实际用法,我们为您准备了出自英文原文的大量英语例句,供您参考。
  bladder cancer recurrence
These results indicate the usefulness of determining the EGF concentration as a marker for detecting bladder cancer recurrence.
      
In conclusion, urinary EGF seems to be a useful marker for detecting bladder cancer recurrence if performed in addition to cytology.
      
A small simulation study is carried out to study the regression parameter estimator and its variance estimator under the discrete Cox model special case and an application to a bladder cancer recurrence dataset is provided.
      
By univariate analysis, VEGF expression and MVD in the biopsy specimens were significant predictors of bladder cancer recurrence.
      
In bladder cancer recurrence monitoring, results were consistently negative until just before detection of a recurrence.
      
更多          
  recurrence of bladder cancer
Then, we tried to clarify the significance of urinary EGF as a marker for recurrence of bladder cancer in comparison with urine cytology.
      
Only one SAE has been reported--a recurrence of bladder cancer in a participant enrolled in the first cohort.
      
Open symbols indicate patients who died before recurrence of bladder cancer.
      
The outcomes analyzed in this study were overall survival and time to first recurrence of bladder cancer.
      
Very few cytogenetic or genetic markers have been identified for predicting the progression or recurrence of bladder cancer.
      
  bladder tumor recurrence
Intravesical recombinant tissue plasminogen activator for the prevention of implantation-mediated bladder tumor recurrence
      
Cell-nuclear data reduction and prognostic model selection in bladder tumor recurrence Dimitris K.
      
In this study, we investigated the feasibility and efficacy of in situ cytokine gene transfer to prevent bladder tumor recurrence.
      


Review of the clinical and pathological data of 36 patients with recurrent bladder cancer showed that factors mentioned below closely relate to tumor progression of bladder cancer, namely, histological grade, muscular layer invasion, urothelial abnormalities, tumor configuration and so on. Probabilities of recurrence and progression should be taken into consideration in planing treatments for patients with bladder cancer when first seen.

本文分析36例复发性膀胱癌的临床和病理资料,发现组织学分级、肌浸润、尿路上皮异常改变、肿瘤构型等因素与膀胱癌的复发进展有密切关系。初诊时应根据复发进展为晚期癌的可能性选择膀胱的治疗方案。

Paraffin-embedded tumor sections from 53 patients with bladder oaneer, and paraffin-embedded bladder mucosa sections from 7 patients with non-neoplastic urologic diseases were taken and stained with SGI-oncpgema 1, a monoclonal antibody against ras oncoprotein P21, and ABO immunohistochemioal procedures. The results were analysed in combination with the histopathologioal grading and slage of the tumors and the outcome of patients. The P21 expression was positive in 32 of the 53 cases (60.4%) with bladder cancer,...

Paraffin-embedded tumor sections from 53 patients with bladder oaneer, and paraffin-embedded bladder mucosa sections from 7 patients with non-neoplastic urologic diseases were taken and stained with SGI-oncpgema 1, a monoclonal antibody against ras oncoprotein P21, and ABO immunohistochemioal procedures. The results were analysed in combination with the histopathologioal grading and slage of the tumors and the outcome of patients. The P21 expression was positive in 32 of the 53 cases (60.4%) with bladder cancer, and negative in all 7 oases with non-neoplastic urologio diseases. We also found that the rates of P21 positive expression decreased with higher tumor grades and stages. Recurrent rates for tumor cases with P21 positive expression was 17.6% and 82 A % for cases with negative P21 expressions. Follow-up analysis revealed that there was a close correlation between the expression of P21 and prognosis. In the 32 patients with P21 positive expression only 3 (9.4%) died of tumor spread and in 21 patients with negative P21 expression 17 (81%) died of tumor spread, indicating that P21 positive expression is a good prognostic parameter for patients with bladder cancer.

本文用癌基因ras产物P_(21)的单克隆抗体SCI-oncogema 1及ABC免疫酶标染色法对53例膀胱癌和7例泌尿系非肿瘤病人的膀胱粘膜石蜡切片进行染色,结合肿瘤的病理学分级和分期以及病人随访结果进行分析,表明弱例膀胱癌中P_(21)阳性者达32例(60.4%),而7例泌尿系非肿瘤病人的膀胱粘膜标本其P_(21)均为阴性。还发现在膀胱癌P_(21)的阳性率随着病理分级和分期的上升而明显下降,P_(21)阳性膀胱癌其复发率为17.6%,而P_(21)阴性膀胱癌的复发率则高达82.4%。经分析还发现P_(21)表达与膀胱癌预后有密切的相关性,32例P_(21)阳性膀胱癌患者中死于肿瘤者仅3例(9.4%),而21例P_(21)阴性膀胱癌患者中死于肿瘤者多达17例(81%)。提示P_(21)阳性可考虑作为膀胱癌预后较好的客观依据之一。

Bladder cancer often appears with multifoci, and the visible tumor foci usually coexist with invisible precancerous lesions which are difficult to treat by conventional therapies. Based on our previous studies we designed this study on inhibitory therapy of precancerous lesions in rat's bladder by whole-bladder-wall laser-irradiation plus hematoporphyrin derivative (HpD). The rats were divided at random into two groups. Group 1 was control, the rats received N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) only....

Bladder cancer often appears with multifoci, and the visible tumor foci usually coexist with invisible precancerous lesions which are difficult to treat by conventional therapies. Based on our previous studies we designed this study on inhibitory therapy of precancerous lesions in rat's bladder by whole-bladder-wall laser-irradiation plus hematoporphyrin derivative (HpD). The rats were divided at random into two groups. Group 1 was control, the rats received N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) only. Group 2 was used for therapy, in which the rats received BBN and Photodynamic therapy(PDT), The rats in both groups were given BBN three times a week for 24 weeks in a dose of 30mg/kg body weight. After 24 weeks the rats in group 2 were treated with the whole-bladder-wall laser-irradiation plus HpD, the dosage of HpD was 20mg/kg b.w. intraperitoneally 48h before, the estimated energy density of the irradiated area was 40 J/cm~2. The period of experiment was 11~13 months, at that time the rats wore killed for histopathological examination. The results showed that the incidence of bladder cancer in group 2 was reduced by 69.7% (X~2=6,09, P<0.05) as compared with control group. We inferred that the inhibition rate of bladder cancer will be increased if the procedure of whole-bladder-wall laser-irradiation plus HpD is carried out two or more times. This re. sult provides a useful reference for clinical trial in preventing precancerous lesions from developing an entity.

膀胱癌常表现为多灶性,如何治疗癌前病变是减少复发、提高治愈率的关键。我们根据先前的研究结果,应用激光全膀胱辐照加血卟啉衍生物的方法,对膀胱癌前病变进行阻断性治疗研究。将大鼠随机分为2组,组1作为对照仅给予致癌物亚硝胺(BBN);组2除给予BBN外,还在2组停止BBN后进行全膀胱辐照光动力学处理一次。致癌物BBN的剂量为30mg/kg体重,每周3次共24周。其后,组2鼠腹腔注射血卟啉衍生物HpD,20mg/kg体重,48小时后用激光辐照全膀胱壁,光能量密度约为40J/cm~2。第11个月后处死动物进行病理组织学检查。结果表明,膀胱癌的发病率治疗组比对照组降低69.7%(x~2=6.09,P<0.05)。作者认为,如果进行2次以上全膀胱激光辐照光动力学处理,膀胱癌变率可能会进一步降低。上述结果为临床预防膀胱癌的复发、提高治愈率提供了应用光动力学疗法的依据

 
<< 更多相关文摘    
图标索引 相关查询

 


 
CNKI小工具
在英文学术搜索中查有关膀胱癌复发的内容
在知识搜索中查有关膀胱癌复发的内容
在数字搜索中查有关膀胱癌复发的内容
在概念知识元中查有关膀胱癌复发的内容
在学术趋势中查有关膀胱癌复发的内容
 
 

CNKI主页设CNKI翻译助手为主页 | 收藏CNKI翻译助手 | 广告服务 | 英文学术搜索
版权图标  2008 CNKI-中国知网
京ICP证040431号 互联网出版许可证 新出网证(京)字008号
北京市公安局海淀分局 备案号:110 1081725
版权图标 2008中国知网(cnki) 中国学术期刊(光盘版)电子杂志社